Adamas Pharmaceuticals Stock Forecast, Price & News

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

Is Adamas Pharmaceuticals a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adamas Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMS, but not buy additional shares or sell existing shares.
View analyst ratings for Adamas Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Adamas Pharmaceuticals?

Wall Street analysts have given Adamas Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adamas Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Adamas Pharmaceuticals.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings data on Sunday, August, 8th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. The specialty pharmaceutical company earned $21.97 million during the quarter, compared to the consensus estimate of $22.24 million.
View Adamas Pharmaceuticals' earnings history.

How has Adamas Pharmaceuticals' stock price been impacted by Coronavirus?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADMS shares have increased by 163.3% and is now trading at $8.03.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ADMS?

6 equities research analysts have issued 12-month target prices for Adamas Pharmaceuticals' shares. Their forecasts range from $6.00 to $12.50. On average, they expect Adamas Pharmaceuticals' stock price to reach $8.90 in the next year. This suggests a possible upside of 10.8% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:

• Neil F. McFarlane, Chief Executive Officer & Director
• Christopher B. Prentiss, Chief Financial Officer (LinkedIn Profile)
• Adrian Quartel, Chief Medical Officer
• Vijay Shreedhar, Chief Commercial Officer (LinkedIn Profile)
• Jill M. Jene, Head-Corporate Development & Strategy

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Adamas Pharmaceuticals' key competitors?

Some companies that are related to Adamas Pharmaceuticals include PureTech Health (PRTC), Bicycle Therapeutics (BCYC), Centessa Pharmaceuticals (CNTA), Protagonist Therapeutics (PTGX), Organogenesis (ORGO), Zealand Pharma A/S (ZEAL), Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), Day One Biopharmaceuticals (DAWN), Vectura Group (VEGPF), COMPASS Pathways (CMPS), uniQure (QURE), Nurix Therapeutics (NRIX), Xenon Pharmaceuticals (XENE) and Aerpio Pharmaceuticals (ARPO).
View all of ADMS's competitors.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $8.03.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals has a market capitalization of $366.14 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57.40 million in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

Adamas Pharmaceuticals employs 138 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

Where are Adamas Pharmaceuticals' headquarters?

Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at (510) 450-3500 or via email at [email protected].